NASDAQ$ZLAB

Zai Lab Limited-ADR · Q2 2025 earnings

Q2 2025 earnings · · Before market open · Investor relations

Briefing

Zai Lab reported Q2 2025 product revenue of $109.1 million, up 9% year-over-year.

Total revenue reached $110.0 million for the quarter. The net loss narrowed to $40.7 million from $80.3 million in the prior-year period, driven by revenue growth and reduced operating expenses. Cash and cash equivalents stood at $732.2 million at quarter end.

  • Product revenue grew 9% to $109.1 million, led by VYVGART, XACDURO, and NUZYRA.
  • Net loss improved 49% to $40.7 million as operating expenses declined.
  • ZEJULA revenue declined 9% amid competitive pressure in the PARPi class.
  • Cash position strengthened to $732.2 million with positive operating cash flow trends.

Headline financials

Total Revenue

$110M

Previous: $101M+9.4%
EPS (adj)

-$0.04

Previous: -$0.08+50.0%
Capital Expenditures

-$4.42M

Previous: -$1.72M-157.7%
Net Income

-$40.7M

Previous: -$80.3M+49.3%
Operating Income

-$54.9M

Previous: -$76.1M+27.8%
Cash & Equivalents

$732M

Previous: $630M+16.2%

Revenue & EPS history

Zai Lab · Revenue · Quarterly

$110M

Q2 2025+9.4%vs Q2 2024
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Revenue by segment

Zai Lab · $86.5M total across 4 segments · Q2 2025

  • ZEJULA
    $41M
  • VYVGART / VYVGART Hytrulo
    $26.5M
  • NUZYRA
    $14.3M
  • XACDURO
    $4.62M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

-0.1%

Avg return

Earnings day

+0.3%

Avg return

5 days after

-0.5%

Avg return

30 days after

45%

13 / 29 earnings

Positive

+26.0%

Q1 2024

Best reaction

-11.2%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2025
Q1 2026-5.9%-7.0%-20.9%
Q4 2025+1.7%-8.6%-7.2%
Q3 2025-6.4%-11.3%-21.4%
Q1 2025+2.5%+0.9%+34.4%
Q4 2024-2.0%-3.1%+6.3%
Q3 2024-3.7%-13.0%-14.1%
Q2 2024-5.6%-7.8%+11.3%
Q1 2024+26.0%+29.0%+19.9%
Q4 2023-0.9%+0.5%-23.7%
Q3 2023+7.4%+0.9%-1.5%
Q2 2023-11.2%-5.4%+3.5%
Q1 2023+1.4%-9.3%-24.2%
Q4 2022-0.6%+7.3%-10.5%
Q3 2022+1.9%+23.9%+18.7%
Q2 2022-5.0%-6.2%-8.0%
Q1 2022-2.1%+30.0%+5.6%
Q4 2021-4.0%-26.0%-19.6%
Q3 2021+0.7%-2.3%-22.3%
Q2 2021+0.6%+0.9%+0.4%
Q1 2021-5.1%-3.3%+8.3%
Q4 2020+0.3%-7.0%-9.6%
Q4 2019-1.4%-2.7%+17.0%
Q1 2020-8.7%+3.1%+18.3%
Q2 2019+4.3%+4.1%-4.0%
Q1 2019+3.7%+6.7%-9.7%
Q4 2018+10.4%+10.4%+1.6%
Q3 2018+6.7%+13.6%+13.1%
Q4 2017-5.3%-8.8%+22.8%
Q3 2017-2.2%-0.6%+0.3%
Q2 2017
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro